

BIO-TECH SYSTEMS, INC.

Market Research in the Health Care Field

NEWS RELEASE

4167 W. Pinecrest Circle
Las Vegas, Nevada 89121

February 1, 2010

(702) 456-7608 (702) 456-2189 FAX
E-Mail: mburns@biotechsystems.com
Web Site: www.biotechsystems.com

FOR IMMEDIATE RELEASE

Contact: Marvin Burns
Tel: (702) 456-7608
Fax: (702) 456-2189

BIO-TECH SYSTEMS ANNOUNCES A NEW RADIOPHARMACEUTICAL REPORT:
Report 310: THE U.S MARKET FOR SPECT AND PET RADIOPHARMACEUTICALS

GOOD PROSPECTS FOR MOST SPECT AND PET RADIOPHARMACEUTICALS, NEW PET PRODUCTS EMERGING FOR CARDIOLOGY AND ONCOLOGY, BIG MARKETS FOR PET AND SPECT NEUROLOGY PRODUCTS FOR ALZHEIMERS'S AND PARKINSON'S, NEW PET MOLECULAR IMAGING PLATFORMS, ANALYSIS AND SALES FORECASTS TO 2017

Bio-Tech Systems Inc. announces the publication of a comprehensive report with detailed analysis of the markets for SPECT and PET radiopharmaceuticals. The report has a strong focus on new products and technology and emerging market opportunities. This covers nuclear cardiology with both PET and SPECT, targeted oncology and new molecular imaging platforms for PET. It also analyzes the large emerging markets for imaging Alzheimer's and Parkinson's disease with PET and SPECT. This will broaden the base of nuclear medicine and allow nuclear imaging to compete more effectively in the larger imaging marketplace.

There has been some decline in the number of SPECT myocardial perfusion procedures as well as reduced pricing for Cardiolite and Myoview because of generic sestamibi. The technetium shortage has also added pressure that will continue for the near term. This will encourage more physicians to adopt PET for many cardiology applications as soon as the new perfusion agents are approved. Cardiology PET produces better images and offers higher reimbursement than traditional cardiology SPECT. This will also stimulate the market for rubidium PET. Growth is still expected in cardiology SPECT from specialized products for imaging myocardial infarction and neuronal imbalances in patients that need pacemakers or may be subject to congestive heart failure. These products are in late stage development and will be introduced in the near term.

New molecular imaging and therapeutic modalities are also being developed based on apoptosis, angiogenesis and PLE (Phospho-Lipid Ether) tumor targeting. This includes new oncology products for diagnosing and monitoring cellular response to therapy. These molecular imaging platforms will also have therapeutic applications, increasing their versatility and usefulness. This will aid in developing patient specific dosimetry necessary for optimizing dosage and evaluating patient response to therapy. In the long run, this will encourage more investment from biopharmaceutical companies and venture groups that will enhance future market growth.

SPECT and PET Radiopharmaceuticals: Market Analysis and Future Prospects

U.S. sales of SPECT and PET radiopharmaceuticals reached \$1.16 billion in 2009 and are expected to rise to \$4.76 billion by 2017. Total SPECT radiopharmaceutical sales were down 11.6% in 2009 primarily due to reductions in pricing of perfusion agents with the introduction of generic sestamibi. SPECT procedure volume was also down due to the technetium shortage. These pressures will continue in 2010, but eventually stabilize. In comparison, PET procedures were flat compared with the previous year, but revenue was down slightly because of price weakness in the FDG market. However, future sales growth will be more in line with procedure growth.

Although PET reimbursement has been under pressure for the past 2 years, there has been some relief recently. New indications have been approved and reimbursement has improved for certain procedures, particularly in cardiology. Investment in new PET agents is increasing in all segments, which bodes well for this market once the new products are introduced.

Continuing improvements in imaging technology in both SPECT and PET are allowing higher resolution and shorter imaging times. Radiopharmaceutical doses are also going down due to increased imaging efficiency. This makes nuclear medicine safer than many other imaging modalities, which are threatened with excessive radiation and patient safety issues.

As new products are introduced, SPECT sales should more than double during the forecast period from \$817 million in 2009 to \$1,737 million by 2017. PET sales will increase more rapidly from \$348 million in 2009 to \$3,028 million by 2017, an increase of more than 700%. This will come primarily from new products as well as increases in the volume of FDG procedures. Market growth will also result from higher prices of the new products. This influx will help all segments of nuclear medicine expanding the platform for molecular imaging. One effect is that clinicians will have more options as alternatives to higher risk and more costly invasive procedures. This will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field.

ABOUT THE AUTHOR

Marvin Burns is president of Bio-Tech Systems, Inc., a firm that focuses on market research in the healthcare field. Burns specializes in market evaluation, where technological and scientific insight is important. The company has prepared numerous market research reports on diagnostic and therapeutic radiopharmaceuticals, brachytherapy, contrast media, interventional cardiology and medical imaging, which have been widely distributed. Burns has also served as a consultant to many international firms and venture groups in these fields. He has also been Technology Editor of Future Oncology, a publication widely circulated in the pharmaceutical and biotechnology industry reporting on new developments in cancer diagnosis and treatment. Burns is a graduate of MIT and Harvard Business School's advanced management program. He has prepared over 100 publications and has 15 patents and invention disclosures. Prior to forming Bio-Tech Systems, he was employed by firms in life sciences, bioinstrumentation and medical imaging fields in general management, marketing and product development. He was also a hospital administrator in charge of professional and technical services including medical imaging, clinical laboratories, therapy services, and materials management.

SPECT AND PET RADIOPHARMACEUTICALS: REPORT CONTENTS

SECTION I: Market Status, Trends and Forecasts

Analysis of sales trends and opportunities in SPECT and PET markets, competitive challenges, new products in the pipeline and prospects for future growth. Also provides sales forecasts in all product categories to 2017. Products include:

- Nuclear cardiology agents for SPECT and PET. (myocardial perfusion, myocardial viability, neuronal imaging and metabolic imaging). New products include Zemeva for myocardial infarction, Androview for neuronal instability and congestive heart failure, new Lantheus and FluoroPharma PET perfusion and neuronal imaging agents.
- Products for functional SPECT imaging. SPECT and PET neurology imaging including new products for Alzheimer's and Parkinson's imaging from Avid, GE and Bayer.
- Oncology products including ProstaScint, Octreoscan and new products for imaging prostate cancer including Trofex from Molecular Insight. Also, PET apoptosis imaging with Aposense, Celectar's PLE product and new molecular imaging platforms.

SECTION II: Radiopharmaceutical Products and Technology

- Technical principles and functional characteristics of radiopharmaceutical agents.
- Radioisotope selection and optimization; production methods and trade-offs.
- Challenges in the technetium shortage and options for new sources of molybdenum-99

SECTION III: Clinical Applications

- Discussion of clinical applications for radiopharmaceutical products and technologies.
- Options in radiopharmaceutical selection for both SPECT and PET imaging.
- Analysis of product characteristics, performance benefits and trade-offs.

SECTION IV: Current Developments and Emerging Technologies

- Description of products in development within each major SPECT and PET market segment including cardiology, neurology and oncology.
- Description of new SPECT and PET agents, such as new myocardial imaging agents, angiogenesis imaging for cellular response to therapy, apoptosis imaging and therapy, PLE (phospho-lipid ether) targeting and therapy.

SECTION V: Industry Analysis

- Analysis of current suppliers with individual product sales and market shares in 2009
- Market distribution, pricing strategies and new products in the pipeline.

SECTION VI: End-User Analysis

- Analysis of end-user groups and comparative requirements for medical imaging.
- Procedure mix and product utilization in hospitals and clinics.

SECTION VII: Company Profiles

- Background information on companies in the field and review of recent performance.
- Discussion of each company's market activities and management strategies

LIST OF EXHIBITS—SPECT AND PET RADIOPHARMACEUTICALS

COMPARATIVE MARKET FOR SPECT AND PET RADIOPHARMACEUTICALS, TOTAL SALES AND PROCEDURE GROWTH FROM 2002-2017

HISTORIC AND FORECAST SALES GROWTH OF SPECT AND PET RADIOPHARMACEUTICALS BY PRODUCT GROUP FROM 2006-2017

2009 DIAGNOSTIC RADIOPHARMACEUTICAL SALES SUMMARY BY PROCEDURE CATEGORY AND PRODUCT TYPE

2017 DIAGNOSTIC RADIOPHARMACEUTICAL SALES SUMMARY BY PROCEDURE CATEGORY AND PRODUCT TYPE

HISTORIC AND FORECAST SPECT CARDIOLOGY MARKET ANALYSIS BY PRODUCT CATEGORY FROM 2007-2010

HISTORIC AND FORECAST CHANGES IN TECHNETIUM PRICING DUE TO INCREASED DEMAND AND SUPPLY SHORTAGES FROM 2002-2017

HISTORIC AND FORECAST MARKET FOR TECHNETIUM GENERATORS, AVERAGE PRICE PER GENERATOR AND PRICE PER CURIE FROM 2002-2017

HISTORIC AND FORECAST SALES OF SPECT CARDIOLOGY PRODUCTS BY PRODUCT CATEGORY AND APPLICATION FROM 2006-2017

HISTORIC AND FORECAST SALES OF PET CARDIOLOGY PRODUCTS BY PRODUCT CATEGORY FROM 2006-2017

HISTORIC AND FORECAST SALES OF SPECT NEUROLOGY PRODUCTS BY PRODUCT CATEGORY FROM 2006-2017

HISTORIC AND FORECAST SALES OF PET NEUROLOGY PRODUCTS BY PRODUCT CATEGORY FROM 2006-2017

HISTORIC AND FORECAST SALES OF SPECT ONCOLOGY PRODUCTS BY PRODUCT CATEGORY FROM 2006-2017

HISTORIC AND FORECAST SALES OF PET ONCOLOGY PRODUCTS BY PRODUCT CATEGORY FROM 2002-2017

HISTORIC AND FORECAST SALES OF GENERAL NUCLEAR PRODUCTS BY PRODUCT CATEGORY AND APPLICATION FROM 2006-2017

HISTORIC AND FORECAST SALES OF TECHNETIUM COLD KITS BY PRODUCT CATEGORY AND APPLICATION FROM 2006-2017

2009 SALES AND MARKET SHARES OF RADIOPHARMACY COMPANIES AND INDEPENDENT NUCLEAR PHARMACIES

ANALYSIS OF RADIOPHARMACY REVENUES, COSTS AND GROSS PROFIT IN 2009

DIAGNOSTIC AND THERAPEUTIC ISOTOPES

CLINICAL INDICATIONS FOR NUCLEAR IMAGING PROCEDURES

2009 DIAGNOSTIC RADIOPHARMACEUTICAL SALES SUMMARY, MANUFACTURERS' SALES DOLLAR VOLUME AND MARKET SHARE

2009 DISTRIBUTION OF RADIOPHARMACEUTICAL SALES IN THE U.S., MANUFACTURER'S SALES DOLLAR VOLUME BY PRODUCT CATEGORY

2009 SALES OF THALLIUM FOR HEART PERFUSION STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF CARDIOLITE FOR HEART PERFUSION STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF MYOVIEW FOR HEART PERFUSION STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF SESTAMIBI FOR HEART PERFUSION STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF CARDIOGEN RUBIDIUM-81 GENERATOR FOR HEART PERFUSION STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF PYP-PYROPHOSPHATE KITS FOR HEART IMAGING, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

LIST OF EXHIBITS—SPECT AND PET RADIOPHARMACEUTICALS

2009 SALES OF TECHNETIUM GENERATORS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF MDP AND HDP KITS FOR BONE IMAGING, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF TECHNETIUM DTPA KITS FOR AEROSOL LUNG VENTILATION, BRAIN AND KIDNEY SCANS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF TECHNETIUM SULFUR COLLOID KITS FOR LIVER SCANS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF MACRO-AGGREGATED ALBUMIN FOR LUNG PERFUSION SCANS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF TECHNETIUM BILIARY AGENTS FOR GALL BLADDER STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF TECHNESCAN MAG 3 FOR KIDNEY FUNCTION STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF IODINE 131 FOR THYROID IMAGING, THERAPY AND KIDNEY SCANS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF IODINE 123 FOR THYROID SCANS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF CERETEC FOR BRAIN PERFUSION STUDIES AND WHITE BLOOD CELL LABELING, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF NEUROLITE FOR IMAGING BRAIN PERFUSION, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF GALLIUM 67 FOR SCANS OF TUMORS, ABSCESSES AND INFLAMMATION, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF XENON FOR LUNG VENTILATION STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF INDIUM OXINE FOR IMAGING INFLAMMATORY PROCESSES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF PROSTASCINT FOR IMAGING PROSTATE CANCER, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF OCTREOSCAN FOR IMAGING NEUROENDOCRINE TUMORS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES OF INDIUM CHLORIDE FOR COMPOUNDING WITH CANCER IMAGING AGENTS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE

2009 SALES DISTRIBUTION OF FDG SUPPLIERS IN THE U.S., NUMBER OF END-USERS, ANNUAL DOSES SOLD AND SALES VOLUME

COMPARATIVE ALLOCATION OF DIAGNOSTIC FACILITIES BY HOSPITAL BED SIZE IN 2009

COMPARATIVE UTILIZATION PARAMETERS FOR DIFFERENT IMAGING MODALITIES IN 2009

DISTRIBUTION OF HOSPITAL DIAGNOSTIC IMAGING PROCEDURES IN THE U.S. BY HOSPITAL BED SIZE IN 2009

RELATIVE PROCEDURE VOLUME IN DIFFERENT IMAGING MODALITIES, PERCENTAGE RELATIONSHIP BY HOSPITAL BED SIZE IN 2009

RELATIVE ACTIVITY INDEX AMONG DIFFERENT IMAGING MODALITIES, PROCEDURES PER BED PER YEAR BY HOSPITAL BED SIZE IN 2009

DISTRIBUTION OF NUCLEAR MEDICINE PROCEDURES IN HOSPITAL AND IMAGING CLINICS IN 2009

COMPANY PROFILES INCLUDE

AECL (Atomic Energy of Canada Ltd.)

COVIDIEN, INC.

ALGETA ASA (Norway)

CYTOGEN CORPORATION

ALPHAMED, INC.

DOW CHEMICAL CO.

ALSERAS PHARMACEUTICALS
MOLECULAR IMAGING

DRAXIMAGE, INC.

AMERICAN RUSSIAN CANCER
ALLIANCE (ARCA)

GE HEALTHCARE

AMIC (American Medical Isotope Corp.)

IBA MOLECULAR

ANSTO (Australian Nuclear Science and
Technology Organization)

IMMUNOMEDICS, INC.

APOSENSE, LTD. (ISRAEL)

LANTHEUS MEDICAL IMAGING INC

AVID RADIOPHARMACEUTICALS INC.

MDS NORDION

BIO-NUCLEONICS, INC.

MOLECULAR INSIGHT
PHARMACEUTICALS INC.

BRACCO DIAGNOSTICS

NTP RADIOISOTOPES (PTY) LTD (NTP)
(South Africa)

CARDINAL HEALTH

P.E.T.NET SOLUTIONS

CELLECTAR, LLC

PHARMALUCENCE, INC.

ORDER FORM

Report No. 310 – US MARKET FOR SPECT AND PET RADIOPHARMACEUTICALS

The report is priced at \$9,500 plus \$4,500 for a multi-user license.

Electronic PDF copies are available at no extra cost..

Please make check payable to: BIO-TECH SYSTEMS, INC.

For wire transfer, make deposit to:

BANK OF AMERICA, NEVADA
Post Office Box 98600
Las Vegas, Nevada 89193-8600
Routing/ABA #122 400 724

For credit to: BIO-TECH SYSTEMS, INC.

Account No. 501 282 7292

Mailing Information

Name: _____ Title: _____

Company: _____

Address _____

City: _____ State _____ Zip Code _____ Country _____

Telephone _____ FAX _____

E-Mail _____

P.O. #: _____ Signature _____

Credit Cards: VISA, MC, AMEX, DISCOVER (Check One)

Credit Card No. _____

Expiration: Month _____ Year _____ Name on Card : _____

Signature _____

Address for Credit Card Statements _____

Return to:

BIO-TECH SYSTEMS, INC.
4167 W. Pinecrest Circle
Las Vegas, Nevada 89121
Telephone: (702) 456-7608 FAX (702) 456-2189
E-Mail: mburns@biotechsystems.com